Table 7 Missense and frameshift mutations for which neo-epitopes have not been predicted in any of the 12 haplotypes considered in the study
From: Lack of shared neoantigens in prevalent mutations in cancer
MISSENSE | TOP FREQ | FRAMESHIFT | TOP FREQ |
|---|---|---|---|
BCORN1459S | ACVR2AK437Rfs*5 | Stomach | |
BRAFV640E/V600E | Colon, Skin, Thyroid | APCT1556Nfs*3 | |
BRAFV640M | BCORL1P1681Qfs*20 | ||
ERBB2S310F | GLI1G274Afs*6 | ||
FBXW7R465C | JAK1K860Nfs*16 | ||
FBXW7R465H | JAK1P430Rfs*2 | ||
FBXW7R479Q | NPM1W317Cfs*12 | ||
FBXW7R505C | PTENK267Rfs*9 | ||
FBXW7R505G | PTENT319* | ||
FGFR2S252W | RPL22K15Rfs*5 | Corpus Uteri | |
FGFR3S249C | Bladder | SALL4V995Ffs*14 | |
GNAQQ209P | ZMYM2K1044Rfs*33 | ||
HRASQ61R | Adrenal gland | ||
IDH1R132C | |||
IDH1R132H | Brain | ||
KRASA146T | |||
KRASG12A | |||
KRASG12C | Lung | ||
KRASG12D | Pancreas, Rectum | ||
KRASG12R | |||
KRASG12S | |||
KRASG12V | |||
KRASG13D | |||
KRAS Q61H | |||
NRASG12D | |||
NRASG13D | |||
NRASG13R | |||
NRASQ61K | |||
NRASQ61L | |||
NRASQ61R | Hematopoietic | ||
PIK3CAC420R | |||
PIK3CAE542K | |||
PIK3CAE545K | Cervix uteri, Larynx | ||
PIK3CAH1047R | Breast | ||
POLEP286R | |||
PTENR130G | Uterus | ||
PTENR130Q | |||
TP53G245S | |||
TP53H179R | |||
TP53H193R | |||
TP53I195T | |||
TP53R175H | Ovary, Esophagus | ||
TP53R248Q | |||
TP53R248W | Bones | ||
TP53R273C | |||
TP53R273H | |||
TP53R273L | |||
TP53R282W | |||
TP53V157F | |||
TP53Y220C |